Free Trial

PROCEPT BioRobotics Q2 2023 Earnings Report

PROCEPT BioRobotics logo
$62.53 +1.63 (+2.68%)
As of 04:00 PM Eastern

PROCEPT BioRobotics EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

PROCEPT BioRobotics Revenue Results

Actual Revenue
$33.10 million
Expected Revenue
$30.25 million
Beat/Miss
Beat by +$2.85 million
YoY Revenue Growth
N/A

PROCEPT BioRobotics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Remove Ads

PROCEPT BioRobotics Earnings Headlines

Procept BioRobotics announces WATER III randomized-controlled trial results
William Blair Keeps Their Buy Rating on PROCEPT BioRobotics (PRCT)
Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
See More PROCEPT BioRobotics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PROCEPT BioRobotics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PROCEPT BioRobotics and other key companies, straight to your email.

About PROCEPT BioRobotics

PROCEPT BioRobotics (NASDAQ:PRCT), a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

View PROCEPT BioRobotics Profile

More Earnings Resources from MarketBeat